ClinicalTrials.gg
CompletedNCT00002084Updated Jun 24, 2005

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

An interventional study of Valacyclovir hydrochloride and Acyclovir in Herpes Simplex and HIV Infections, sponsored by Glaxo Wellcome. Completed at 46 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.

No phase
5 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
4 of 24
Glaxo Wellcome

Among the 24 studies testing valacyclovir in Herpes Simplex, this one is one of 5 with no phase, and was the 1st registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing valacyclovir in Herpes Simplex as a file.
02

Study summary

To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.

03

Conditions studied

  • Herpes Simplex
  • HIV Infections

Keywords

  • Acyclovir
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Antiviral Agents
  • Anus Diseases
  • Herpes Genitalis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • infection with = or > 100 cells/mm3.
  • Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
  • History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

  • Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.

Concurrent Medication:

Excluded:

  • Systemic antiherpes medication.
  • Interferon.

Patients with the following prior conditions are excluded:

History of to acyclovir.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
06

Study locations

46 sites
  • Univ of South Alabama
    Mobile, Alabama 36604, United States
  • Univ of Arizona / Health Science Ctr
    Tucson, Arizona 85724, United States
  • Combat Group
    Los Angeles, California 90028, United States
  • Los Angeles County - USC Med Ctr
    Los Angeles, California 90033, United States
  • Infectious Disease Med Group / Adult Immunology Clinic
    Oakland, California 94609, United States
  • UCI Med Ctr
    Orange, California 92668, United States
  • UCSD Med Ctr
    San Diego, California 92103, United States
  • San Diego Naval Hosp
    San Diego, California 921345000, United States
  • ViRx Inc
    San Francisco, California 94103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Dr Marcus Conant
    San Francisco, California 94115, United States
  • West Haven Veterans Administration Med Ctr
    West Haven, Connecticut 06516, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Whitman - Walker Clinic
    Washington, District of Columbia 20009, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Veterans Administration Med Ctr / Regional AIDS Program
    Washington, District of Columbia 20422, United States
  • Univ of South Florida
    St. Petersburg, Florida 33705, United States
  • Emory Univ School of Medicine
    Atlanta, Georgia 30303, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Northwestern Memorial Hosp
    Chicago, Illinois 60611, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Infectious Diseases Research Clinic / Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Univ of Iowa Hosp & Clinic
    Iowa City, Iowa 52242, United States
  • Univ of Kansas School of Medicine
    Wichita, Kansas 67214, United States
  • Univ of Maryland at Baltimore
    Baltimore, Maryland 21201, United States
  • St Paul Ramsey Med Ctr
    St. Paul, Minnesota 55101, United States
  • Univ of Mississippi Med Ctr
    Jackson, Mississippi 39216, United States
  • Univ of Missouri at Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • St Louis Univ
    St. Louis, Missouri 63104, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • Univ of Rochester Med Ctr
    Rochester, New York 14642, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Buckley Braffman Stern Med Associates
    Philadelphia, Pennsylvania 19107, United States
  • Univ of Pittsburgh / Graduate School of Public Health
    Pittsburgh, Pennsylvania 15261, United States
  • Roger Williams Med Ctr
    Providence, Rhode Island 02908, United States
  • Regional Med Ctr at Memphis
    Memphis, Tennessee 38103, United States
  • Dallas Associated Dermatologists
    Dallas, Texas 75246, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77550, United States
  • Thomas Audetta Clinic
    Houston, Texas 77006, United States
  • Baylor College of Medicine / Texas Med Ctr
    Houston, Texas 77030, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • MacGregor Med Association
    Houston, Texas 77054, United States
  • Univ TX Med Branch / Ctr for Clinical Studies
    Nassau Bay, Texas 77058, United States
  • Med College of Virginia
    Richmond, Virginia 232980049, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002084
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valacyclovir · Acyclovir

Start the discussion